EMA Authorised: Namuscla (Mexiletine hydrochloride) — Lupin Europe GmbH

View source ↗

Summary

Namuscla (mexiletine hydrochloride) by Lupin Europe GmbH has been authorised for myotonic disorders in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Disorders

Drugs mentioned

• Namuscla (Mexiletine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Myotonic Disorders. MAH: Lupin Europe GmbH. Decision date: 28/05/2026. Orphan medicine